Trial Condition(s):

Pelvic Inflammatory Disease

A Trial Comparing Moxifloxacin versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease

Bayer Identifier:

11981

ClinicalTrials.gov Identifier:

NCT00453349

EudraCT Number:

2006-000874-56

EU CT Number:

Not Available

Study Completed

Trial Purpose

To assess the efficacy and safety of oral moxifloxacin compared to oral levofloxacin plus oral metronidazole in uncomplicated pelvic inflammatory disease (PID)

Inclusion Criteria
-  Diagnosis of uncomplicated PID based on the absence of pelvic or tubo-ovarian abscess at pelvic ultrasound and/or laparoscopic examination.
Exclusion Criteria
-  Subjects with impaired liver and renal function; known hypersensitivity to study drugs, related compounds or any of the excipients.

Trial Summary

Enrollment Goal
460
Trial Dates
black-arrow
Phase
3
Could I receive a placebo?
No
Products
Avelox (Moxifloxacin hydrochloride, BAY12-8039)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Locations
Locations

Obstetrics & Gynecology Hosp. of Fudan Univ.

Shanghai, China, 200011

Locations

Peking Univ. First Hosp.

Beijing, China, 100034

Locations

Shengjing Hosp. of China Medical Univ.

Shenyang, China, 110004

Locations

National Taiwan University Hospital

Taipei, Taiwan, China, 10002

Locations

Chung Shan Medical University Hospital

Taizung, Taiwan, China, 402

Locations

Mahidol University

Bangkok, Thailand, 10700

Locations

Peking University Third Hospital

Beijing, China, 100083

Locations

West China Hospital, Sichuan University

Chengdu, China, 610041

Locations

2nd Hosp., Chongqing Medical Univ.

Chongqing, China, 400010

Locations

Bunda Hospital

Jakarta, Indonesia

Locations

HanYang University Medical Center

Seoul, South Korea, 133792

Locations

Philippine General Hospital

Manila, Philippines

Locations

Ziauddin Medical University Hospital

Karachi, Pakistan

Trial Design